Effect of a low-dose ethinylestradiol and gestodene in combination on the frequency of micronuclei in human peripheral blood lymphocytes of healthy women in vivo

Contraception

Volumn 69, Issue 4, 2004, Pages 327-331

  Lončar, Dragan ^a   Milosevic Djordjevic, Olivera ^b   Živanović, Aleksandar ^a   Grujičić, Darko ^b   Arsenijević, Slobodan ^a  

^a Department of Obstetrics and Gynecology   (Serbia)

^b UNIVERSITY OF KRAGUJEVAC   (Serbia)

Author keywords

Ethinylestradiol; Genotoxicity; Gestodene; Micronuclei; Patients; Peripheral blood lymphocytes

Indexed keywords

ETHINYLESTRADIOL; GESTODENE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINESIS; DRUG EFFECT; EVALUATION; FEMALE; HUMAN; LOW DRUG DOSE; LYMPHOCYTE; MENSTRUAL CYCLE; MICRONUCLEUS; MUTAGENESIS; NORMAL HUMAN;

EID: 18844478378     PISSN: 00107824     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.contraception.2003.12.005     Document Type: Article

References (39)

1. th rev. ed:1993;The Pharmaceutical Press, London.
2. Gimes G, Valent S. [Clinical experiences with a gestodene containing oral contraceptive (Femoden)]. Acta Pharm Hung 1998;68:289-93 [in Hungarian].
3. Merchiers E., Thiery M., Van Kets H., Parewijck W., Defoort P., Martens G. Gestodene clinical experience with an innovative progestogen used in a combination oral contraceptive preparation. Acta Ther. 16:1990;129-138.
4. Lello S., Monterubbianesi M., Guardianelli F., Bianchi C., Simonelli C. Clinical trial of a monophasic estroprogestin oral formulation containing 20 μg ethinyl estradiol and 75 μg gestodene. Gynecol Endocrinol. 15:2001;265-271.
5. UK National Case-Control Study Group. Oral contraceptive use and breast cancer risk in young women. Lancet. i:1989;973-982.
6. Olsson H., Ranstam J., Baldetorp B., et al. Proliferation and DNA ploidy in malignant breast tumors in relation to early oral contraceptive use and early abortions. Cancer. 67:1991;1285-1290.
7. The WHO Collaborative Study of Neoplasia and Steroid Contraceptives. Endometrial cancer and combined oral contraceptives. Int J Epidemiol. 17:1988;263-269.
8. The WHO Collaborative Study of Neoplasia and Steroid Contraceptives. Epithelial ovarian cancer and combined oral contraceptives. Int J Epidemiol. 18:1989;538-545.
9. Royal J., Becher H., Chang-Claude J. Low-dose oral contraceptives protective effect on ovarian cancer risk. Int J Cancer. 95:2001;370-374.
10. Schluster D., Burstein S., Cooke B.A. Molecular endocrinology of the steroid hormones. 1976;Wiley & Sons, New York.
11. Liehr J.G. Genotoxic effects of estrogens. Mutat Res. 238:1990;269-276.
12. Banerjee S.K., Banerjee S., Li S.A., Li J.J. Induction of chromosome aberrations in Syrian hamster renal cortical cells by various estrogens. Mutat Res. 311:1994;191-197.
13. Shyama S.K., Abdulrahiman M., Vijayalaxmi K.K. Genotoxic effect of Anovlar 21, an oral contraceptive, on mouse bone marrow. Mutat Res. 260:1991;47-53.
14. Shyama S.K., Rahiman M.A. Genotoxicity of Lynoral (ethinylestradiol, an oestrogen) in mouse bone marrow cells in vivo. Mutat Res. 370:1996;175-180.
15. Fenech M., Morley A.A. Measurement of micronuclei in lymphocytes. Mutat Res. 147:1985;29-36.
16. Fenech M., Morley A.A. Kinetochore detection in micronuclei an alternative method for measuring chromosome loss. Mutagenesis. 4:1989;98-104.
17. Fenech M. Chromosomal biomarkers of genomic instability relevant to cancer. Drug Discov Today. 7:2002;1128-1137.
18. Bonassi S., Bolognesi C., Abbondandelo A., et al. Influence of sex on cytogenetic end points evidence from a large human sample and review of the literature. Cancer Epidemiol. 4:1995;671-679.
19. Fenech M. The advantages and disadvantages of the cytokinesis-block micronucleus method. Mutat Res. 392:1997;11-18.
20. Edwards J.H. Chromosome analysis from capillary blood. Cytogenetics. 1:1962;90-96.
21. Froland A. A micromethod for chromosome analysis on peripheral blood cultures. Lancet. 2:1962;1281-1282.
22. Milosevic-Djordjevic O., Grujičić D., Marinković D., Arsenijević S., Banković S. Effect of various doses of gestogens on micronuclei frequency in human peripheral blood lymphocytes of pregnant women. Hum Reprod. 18:2003;433-436.
23. Botta A., Occhipinti P., Bartfai E., Orsiere T. Genotoxic effects of potassium dichromate in cultural human lymphocyte. Med Sci Res. 24:1996;797-799.
24. Augusto L.G.D., Lieber S.R., Ruiz M.A., Dosouza C.A. Micronucleus monitoring to assess human occupational exposure to organochlorides. Environ Mol Mutagen. 29:1997;46-52.
25. Grujičić D., Milošević O., Marinković D., et al. Effect of gestagens on micronucleus frequency in human peripheral blood lymphocytes. Balkan J Med Genet. 2:1999;23-28.
26. Bukvić N., Susca F., Bukvić D., Fanelli M., Guanti G. 17α ethinylestradiol and norgestrel combination induce micronucleus increases and aneuploidy in human lymphocyte and fibroblasts cultures. Teratog Carcinog Mutagen. 20:2000;147-159.
27. Reimann R., Kalweit S., Long R. Studies for a genotoxic potential of some endogenous and exogenous sex steroids. II. Communication examination for the induction of cytogenetic damage using the chromosomal aberration assay on human lymphocytes in vitro and the mouse bone marrow micronucleus test in vivo. Environ Mol Mutagen. 28:1996;133-144.
28. Hill A., Wolff S. Sister chromatid exchanges and cell division delays induced by diethylstilbestrol, estradiol and estriol in human lymphocytes. Cancer Res. 43:1983;4114-4118.
29. Banduhn N., Obe G. Mutagenicity of methyl 2-benzimidazol carbamate, diethylstilbestrol and estradiol structural chromosomal aberrations, sister chromatid exchanges, C-mitoses, polyploidies and micronuclei. Mutat Res. 156:1985;199-218.
30. Kabarity A., Mazrooei S. Further investigations on the cytological effects of some contraceptives. Mutat Res. 135:1984;181-188.
31. Pylkkanen L., Johnukainen K., Parvinen M., Santti R. Testicular toxicity and mutagenicity of steroidal and non-steroidal estrogens in the male mouse. Mutat Res. 261:1991;181-191.
32. Fridrichova I. Cytogenetic study of blood in women who had used oral contraceptives. Neoplasma. 7:1990;545-553.
33. Dhillon V.S., Singh J.R., Singh H., Kler R.S. In vitro and in vivo genotoxicity evaluation of hormonal drugs v. mestranol. Mutat Res. 322:1994;173-183.
34. Huber R., Braselmann H., Bauchinger M. Intra and inter-individual variation of background and radiation-induced micronucleus frequencies in human lymphocytes. Int J Radiol Biol. 61:1992;655-661.
35. Koteles G.J., Bojtor I., Szirmal S., Berces J., Otos M. Micronucleus frequency in cultured lymphocytes of an urban population. Mutat Res. 319:1993;267-271.
36. Saritha T.B., Ahuja R.Z. Inter-individual variation in chromosome aberration response to treatment with aphidicolin and folate deficiency. Med Sci Res. 18:1990;785-787.
37. Milosevic-Djordjevic O., Marinković D., Arsenijević S. Genetic determination of sister-chromatid exchange variation in nonstimulated human lymphocytes after treatment with cytostatics in vitro. Genetika. 28:1996;185-192.
38. Dutkowski R.T., Kevin M.J., Jenkins E.C. The effect of oral contraceptives on sister-chromatid exchange, blast transformation, mitotic index and micronuclei formation. Exp Cell Biol. 51:1983;115-120.
39. Di Giorgio C., De Meo M.P., Laget M., Guirand H., Botta A., Dumenil G. The micronucleus assay in human lymphocytes screening for inter-individual variability and application to biomonitoring. Carcinogenesis. 15:1994;313-317.